EVO101
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hidradenitis Suppurativa (HS)
Conditions
Hidradenitis Suppurativa (HS)
Trial Timeline
Dec 3, 2024 → May 1, 2025
NCT ID
NCT06645821About EVO101
EVO101 is a phase 1 stage product being developed by Evommune for Hidradenitis Suppurativa (HS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06645821. Target conditions include Hidradenitis Suppurativa (HS).
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06645821 | Phase 1 | Recruiting |
| NCT05579899 | Phase 2 | Completed |
Competing Products
20 competing products in Hidradenitis Suppurativa (HS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab (M1095) + Adalimumab | MoonLake Immunotherapeutics | Phase 2 | 47 |
| Eltrekibart + Placebo | Eli Lilly | Phase 2 | 52 |
| Placebo + LY3041658 | Eli Lilly | Phase 2 | 52 |
| Placebo + Adalimumab | AbbVie | Approved | 85 |
| Lutikizumab + Placebo | AbbVie | Phase 3 | 77 |
| Adalimumab | AbbVie | Pre-clinical | 23 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 77 |
| adalimumab + placebo | AbbVie | Phase 3 | 77 |
| Lutikizumab | AbbVie | Phase 2 | 52 |
| adalimumab | AbbVie | Phase 3 | 77 |
| Lutikizumab + Placebo | AbbVie | Phase 2 | 52 |
| Risankizumab + Placebo for risankizumab | AbbVie | Phase 2 | 52 |
| adalimumab | AbbVie | Phase 3 | 77 |
| adalimumab + placebo | AbbVie | Phase 3 | 77 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 52 |
| MEDI8968 + Saline | AstraZeneca | Phase 2 | 52 |